[1]
G. Perletti, “Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer”, AIUA, vol. 88, no. 1, pp. 74-75, Mar. 2016.